With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III Toronto, Ontario (November 16, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today it has signed a…


Previous articlePT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences
Next articleCaaMTech Teams Up With University of Wyoming to Study Psychedelics as Treatments for Addiction